S
Stuart M. Lichtman
Researcher at North Shore University Hospital
Publications - Â 49
Citations - Â 4323
Stuart M. Lichtman is an academic researcher from North Shore University Hospital. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 25, co-authored 49 publications receiving 4197 citations. Previous affiliations of Stuart M. Lichtman include University of Chicago & University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Tarun Wasil,Franco Fais,Franco Fais,Franco Fais,Fabio Ghiotto,Fabio Ghiotto,Fabio Ghiotto,Angelo Valetto,Angelo Valetto,Angelo Valetto,Steven L. Allen,Steven L. Allen,Steven L. Allen,Aby Buchbinder,Aby Buchbinder,Aby Buchbinder,Daniel R. Budman,Daniel R. Budman,Daniel R. Budman,Klaus Dittmar,Klaus Dittmar,Klaus Dittmar,Jonathan E. Kolitz,Jonathan E. Kolitz,Jonathan E. Kolitz,Stuart M. Lichtman,Stuart M. Lichtman,Stuart M. Lichtman,Philip Schulman,Philip Schulman,Philip Schulman,Vincent Vinciguerra,Vincent Vinciguerra,Vincent Vinciguerra,Kanti R. Rai,Kanti R. Rai,Kanti R. Rai,Manlio Ferrarini,Manlio Ferrarini,Manlio Ferrarini,Nicholas Chiorazzi,Nicholas Chiorazzi,Nicholas Chiorazzi +45 more
TL;DR: In this paper, cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available.
Journal ArticleDOI
Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.
Zev M. Sthoeger,Mariko Wakai,D B Tse,Vincent Vinciguerra,Steven L. Allen,Daniel R. Budman,Stuart M. Lichtman,Philip Schulman,Lora Weiselberg,Nicholas Chiorazzi +9 more
TL;DR: CD5-expressing B lymphocytes from patients with selected chronic lymphoproliferative disorders were used to determine whether monoclonal populations of CD5+ human B cells produce autoantibodies, and several react with dsDNA, a specificity not previously reported and often seen in association with significant autoimmune disorders.
Journal ArticleDOI
Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine.
Daniel R. Budman,Neal J. Meropol,Bruno Reigner,Patrick J. Creaven,Stuart M. Lichtman,Elmer Berghorn,Joanne Behr,R. J. Gordon,Bruno Osterwalder,Thomas Griffin +9 more
TL;DR: The suggested phase II dose on a continuous 42-day dosing schedule is 1,331 mg/m2/d, and linear pharmacologic parameters of the parent compound and metabolites are demonstrated.
Journal Article
Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia.
Davide Serrano,Joanita Monteiro,Steven L. Allen,Jonathan E. Kolitz,Philip Schulman,Stuart M. Lichtman,Aby Buchbinder,Vincent Vinciguerra,Nicholas Chiorazzi,Peter K. Gregersen +9 more
TL;DR: A comprehensive analysis of the CD4+ and CD8+ T cell repertoire in a population of CLL patients and age-matched controls points to a role for clonal T cell populations in the pathogenesis of this disease.
Journal ArticleDOI
Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells.
Shiori Hashimoto,Mariella Dono,Mariko Wakai,Steven L. Allen,Stuart M. Lichtman,Philip Schulman,Vincent Vinciguerra,Manlio Ferrarini,Jack Silver,Nicholas Chiorazzi +9 more
TL;DR: The data indicate that a subset of CD5+ CLL B cells can display Ig V region gene mutations, consistent with the notions that in some cases antigen selection of these mutations may have occurred, and that antigen stimulation may be a promoting factor in the evolution of certain CLL clones.